It was discovered that CD38 was highly expressed in mm, and anti-CD38 monoclonal antibody offers a promising alternative to the treatment of MM.16 Daratumumab can directly bind to CD38 on the membrane of myeloma cells and induce myeloma cell death through multiple mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis and direct apoptosis, thereby achieving rapid remission of the disease.17 CD38-targeted Daratumumab represents a major milestone in the development of RRMM immunotherapy. The gene discussed is CD38; the disease is plasma cell myeloma.